文献速递淋巴瘤

奥妥珠单抗对比利妥昔单抗用于适合移植的套细胞淋巴瘤患者

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma.
PubMed 文献 · Blood · 2024-01-01

在LyMa-101试验中,初诊套细胞淋巴瘤患者接受化疗联合奥妥珠单抗(O)诱导后移植,继以O维持;倾向性评分匹配后与接受利妥昔单抗(R)相同方案的患者比较。O组诱导结束时骨髓可测量残留病(MRD)阴性率高于R组(83.1% vs 63.4%,P=0.007),5年无进展生存(PFS)和总生存(OS)均优于R组。

要点

  • LyMa-101中O组(n=85)估算5年PFS为83.4%,5年OS为86.9%。
  • 诱导结束骨髓MRD阴性率O组83.1% vs R组63.4%(P=0.007)。
  • 匹配后O组5年PFS 82.8% vs R组66.6%(HR 1.99),5年OS 86.4% vs R组71.4%(HR 2.08)。

核心结论

  • 适合移植的套细胞淋巴瘤患者中,移植前及维持阶段使用奥妥珠单抗较利妥昔单抗提供更好的疾病控制并提高PFS和OS。

研究设计与样本

  • LyMa-101为前瞻性试验,初诊套细胞淋巴瘤患者接受化疗联合奥妥珠单抗后移植,继以奥妥珠单抗维持(O组)。
  • 采用倾向性评分匹配(PSM)将O组与接受相同治疗设计但以利妥昔单抗替代奥妥珠单抗的患者(R组)进行比较。
  • 比较指标为诱导结束时(EOI)可测量残留病(MRD)、无进展生存(PFS)和总生存(OS)。
  • LyMa-101纳入85例患者;PSM后形成两组各82例、基线特征可比的患者。

主要发现

  • LyMa-101中自入组起估算5年PFS为83.4%(95%CI 73.5-89.8),5年OS为86.9%(95%CI 77.6-92.5)(n=85)。
  • 诱导结束时O组骨髓MRD阴性率83.1% vs R组63.4%(χ2检验,P=0.007)。
  • 自治疗开始起,O组估算5年PFS 82.8% vs R组66.6%(P=0.029;HR 1.99;95%CI 1.05-3.76)。
  • 自治疗开始起,O组估算5年OS 86.4% vs R组71.4%(P=0.039;HR 2.08;95%CI 1.01-4.16)。
  • 两组死亡原因相当,最常见为淋巴瘤。

关键数值与推荐

  • 诱导结束时骨髓MRD阴性率:O组83.1% vs R组63.4%(χ2检验,P=0.007)。
  • 5年PFS:O组82.8% vs R组66.6%(P=0.029;HR 1.99;95%CI 1.05-3.76)。
  • 5年OS:O组86.4% vs R组71.4%(P=0.039;HR 2.08;95%CI 1.01-4.16)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Obinutuzumab (O) and rituximab (R) are 2 CD antibodies that have never been compared in a prospective randomized trial of mantle cell lymphoma (MCL). Herein, we report the long-term outcome of the LyMa-101 trial, in which newly diagnosed patients with MCL were treated with chemotherapy plus O before transplantation, followed by O maintenance (O group). We then compared these patients with those treated with the same treatment design with R instead of O (R group). A propensity score matching (PSM) was used to compare the 2 populations (O vs R groups) in terms of measurable residual disease (MRD) at the end of induction (EOI), progression-free survival (PFS), and overall survival (OS). In LyMa-101, the estimated 5-year PFS and OS after inclusion (n = 85) were 83.4% (95% confidence interval [CI], 73.5-89.8) and 86.9% (95% CI, 77.6-92.5), respectively. At EOI, patients treated in the O group had more frequent bone marrow MRD negativity than those treated in the R group (83.1% vs 63.4%; χ2, P = .007). PSM resulted in 2 sets of 82 patients with comparable characteristics at inclusion. From treatment initiation, the O group had a longer estimated 5-year PFS (P = .029; 82.8% vs 66.6%; hazard ratio [HR], 1.99; 95% confidence interval (CI), 1.05-3.76) and OS (P = .039; 86.4% vs 71.4%; HR, 2.08; 95% CI, 1.01-4.16) compared with the R group. Causes of death were comparable in the 2 groups, the most common cause being lymphoma. O before transplantation and in maintenance provides better disease control and enhances PFS and OS compared with R in transplant-eligible patients with MCL. These trials were registered at www.clinicaltrials.gov as #NCT00921414 and NCT02896582.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Sarkozy C, Callanan M, Thieblemont C, et al. Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma. Blood. 2024. PMID: 38669626. doi:10.1182/blood.2024023944

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。